Katherine Chen
Ophthalmology · Irvine, CANPI 1699237420
Payments from drug & device makers
Across 76 payments — averaging $72.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- NEW World Medical,inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$548
- Glaukos Corporation$342
- Sun Pharmaceutical Industries Inc.$217
- Biotissue Holdings Inc.$189
- plus $956 from 10 others
What the payments were for
- Speaking & faculty fees$1,20022%
- Travel & lodging$1,47427%
- Food & beverage$2,75550%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $2,078 |
| NEW World Medical,inc. | 1 | $1,200 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $548 |
| Glaukos Corporation | 6 | $342 |
| Sun Pharmaceutical Industries Inc. | 5 | $217 |
| Biotissue Holdings Inc. | 5 | $189 |
| Bausch & Lomb Americas Inc. | 3 | $164 |
| Alcon | 2 | $163 |
| AbbVie(2 entities) | 3 | $156 |
| Harrow Eye, LLC | 6 | $141 |
| Rxsight Inc | 3 | $115 |
| Oyster Point Pharma, Inc. | 5 | $92 |
| Thea Pharma Inc. | 3 | $60 |
| Sight Sciences, Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$1,458
- Crystalens Accommodating IOL (AT-52AO)$1,458
- Trulign IOL$1,458
- Akreos AO IOL$1,458
- enVista MX60 IOL$1,458
- Kahook Dual Blade$1,200
- Clearpath$1,200
- Ahmed Glaucoma Valve$1,200
- Streamline$1,200
- LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE$377
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$377
- MEIBOMIAN GLAND EVALUATOR$377
- LIPIVIEW OCULAR SURFACE INTERFEROMETER$377
- Clareon PanOptix Pro$147
- MIEBO$124
- VYZULTA$123
- CEQUA$114
How this compares
$5,530 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 27 | $421,398 |
| RestasisCyclosporine | 99 | $89,876 |
| XiidraLifitegrast | 72 | $57,681 |
| CequaCyclosporine | 55 | $34,125 |
| MieboPerfluorohexyloctane/Pf | 31 | $31,615 |
| VevyeCyclosporine | 18 | $13,594 |
| Cyclosporine | 46 | $12,219 |
| Prednisolone Acetate | 196 | $9,418 |
| RhopressaNetarsudil Mesylate | 19 | $5,966 |
| Loteprednol Etabonate | 23 | $5,183 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $5,057 |
| MoxifloxacinMoxifloxacin Hcl | 141 | $3,447 |
| ValacyclovirValacyclovir Hcl | 43 | $2,752 |
| Brimonidine Tartrate | 41 | $2,101 |
| Travoprost | 19 | $1,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $22 | $421,39827 claims |
| AbbVieRestasis, Combigan | $156 | $94,934123 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $164 | $89,297103 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $217 | $34,12555 claims |
| Harrow Eye, LLCVevye | $141 | $13,59418 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $2,078 | $5,18323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Irvine
- Eran DuzmanIrvine$2.4M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.